| Literature DB >> 32948557 |
Chi Chin Sun1,2,3, Ting-Shuo Huang4, Tsai-Sheng Fu5, Chia-Yi Lee6, Bing-Yu Chen3, Fang-Ping Chen7.
Abstract
OBJECTIVES: Visual impairment is an important risk factor for fracture in the elderly population. Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment in elderly people. This study was conducted to explore the relationship between AMD and incident fractures in patients with osteoporosis (OS).Entities:
Keywords: bone diseases; epidemiology; hip; medical retina; ophthalmology; trauma management
Mesh:
Year: 2020 PMID: 32948557 PMCID: PMC7500305 DOI: 10.1136/bmjopen-2020-037028
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flowchart of the patient selection in AMD and non-AMD cohort with a one-to-four match. AMD, age-related macular degeneration.
Baseline characteristics between the AMD and non-AMD groups
| AMD (n=13 584) | Non-AMD (n=54 336) | P value | |
| Age, median (IQR) | 73.8 (67.2–79.3) | 73.8 (67.2–79.3) | 1 |
| Age group, No (%) | |||
| ≥50 to <60 | 1277 (9.4) | 5075 (9.3) | 0.98 |
| ≥60 to <70 | 3372 (24.8) | 13 424 (24.7) | |
| ≥70 to <80 | 5881 (43.3) | 23 603 (43.4) | |
| 80 | 3054 (22.5) | 12 234 (22.5) | |
| Sex, No (%) | |||
| Female | 8081 (59.5) | 32 324 (59.5) | 1 |
| Rheumatologic diseases, No (%) | 846 (6.2) | 3384 (6.2) | 1 |
| DM without complications, No (%) | 4101 (30.2) | 16 404 (30.2) | 1 |
| DM with complications, No (%) | 1629 (12.0) | 6516 (12.0) | 1 |
| Malignancy, No (%) | 1470 (10.8) | 5880 (10.8) | 1 |
| Moderate to severe liver diseases, No (%) | 19 (0.1) | 76 (0.1) | 1 |
| Hyperthyroidism, No (%) | 204 (1.5) | 816 (1.5) | 1 |
| Chronic renal diseases, No (%) | 598 (4.4) | 2392 (4.4) | 1 |
| Cataract, No (%) | 10 276 (75.6) | 41 104 (75.6) | 1 |
| Corneal disease, No (%) | 2665 (19.6) | 10 660 (19.6) | 1 |
| Glaucoma, No (%) | 2037 (15.0) | 8148 (15.0) | 1 |
| CCIs, median (IQR) | 5.00 (3.00–7.00) | 5.00 (3.00–7.00) | 0.22 |
AMD, age-related macular degeneration; CCIs, Charlson Comorbidity Index score; DM, diabetes mellitus; No, number of patients.
Figure 2Estimates of cumulative hazards of transition among patients with OS. OS, osteoporosis.
The effect of AMD on transition of fractures and death
| Osteoporosis to death | Osteoporosis to spine fracture | Osteoporosis to hip fracture | Osteoporosis to humero-radio-ulnar fracture | |||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| AMD | ||||||||
| No | N/A | Reference | Reference | Reference | ||||
| Yes | N/A | N/A | 1.09 (1.04 to 1.15) | <0.001 | 1.18 (1.08 to 1.30) | 0.001 | 0.98 (0.90 to 1.06) | 0.599 |
| Age | ||||||||
| 50–59 | Reference | Reference | Reference | Reference | ||||
| 60–69 | 1.46 (1.28 to 1.66) | <0.001 | 2.37 (2.11 to 2.66) | <0.001 | 3.03 (2.21 to 4.16) | <0.001 | 1.08 (0.96 to 1.22) | 0.203 |
| 70–79 | 2.67 (2.36 to 3.02) | <0.001 | 3.71 (3.31 to 4.15) | <0.001 | 7.92 (5.85 to 10.73) | <0.001 | 1.25 (1.12 to 1.41) | <0.001 |
| >80 | 4.72 (4.16 to 5.36) | <0.001 | 4.70 (4.19 to 5.29) | <0.001 | 16.33 (12.04 to 22.16) | <0.001 | 1.20 (1.05 to 1.37) | 0.007 |
| Sex | ||||||||
| Female | Reference | Reference | Reference | Reference | ||||
| Male | 1.30 (1.24 to 1.36) | <0.001 | 0.58 (0.55 to 0.61) | <0.001 | 0.66 (0.61 to 0.72) | <0.001 | 0.42 (0.39 to 0.46) | <0.001 |
| Rheumatologic diseases | ||||||||
| No | Reference | Reference | Reference | Reference | ||||
| Yes | 1.11 (1.03 to 1.20) | 0.005 | 1.20 (1.12 to 1.29) | <0.001 | 1.10 (0.96 to 1.26) | 0.156 | 1.11 (1.00 to 1.24) | 0.059 |
| DM without complications | ||||||||
| No | Reference | Reference | Reference | Reference | ||||
| Yes | 1.27 (1.21 to 1.34) | <0.001 | 1.00 (0.95 to 1.05) | 0.957 | 1.04 (0.94 to 1.15) | 0.399 | 1.12 (1.04 to 1.22) | 0.005 |
| DM with complications | ||||||||
| No | Reference | Reference | Reference | Reference | ||||
| Yes | 1.41 (1.33 to 1.50) | <0.001 | 0.99 (0.92 to 1.06) | 0.717 | 1.50 (1.33 to 1.69) | <0.001 | 1.05 (0.94 to 1.17) | 0.37 |
| Malignancy | ||||||||
| No | Reference | Reference | Reference | Reference | ||||
| Yes | 4.41 (4.19 to 4.63) | <0.001 | 1.09 (1.03 to 1.16) | 0.004 | 1.02 (0.92 to 1.15) | 0.666 | 1.03 (0.93 to 1.14) | 0.581 |
| Moderate to severe liver diseases | ||||||||
| No | Reference | Reference | Reference | Reference | ||||
| Yes | 4.69 (4.24 to 5.18) | <0.001 | 1.29 (0.99 to 1.69) | 0.06 | 1.06 (0.63 to 1.80) | 0.817 | 0.69 (0.40 to 1.19) | 0.178 |
| Hyperthyroidism | ||||||||
| No | Reference | Reference | Reference | Reference | ||||
| Yes | 0.90 (0.76 to 1.06) | 0.2 | 1.07 (0.93 to 1.23) | 0.338 | 1.19 (0.91 to 1.56) | 0.203 | 1.15 (0.95 to 1.39) | 0.151 |
| Chronic renal diseases | ||||||||
| No | Reference | Reference | Reference | Reference | ||||
| Yes | 2.22 (2.10 to 2.35) | <0.001 | 1.01 (0.93 to 1.10) | 0.786 | 1.57 (1.38 to 1.77) | <0.001 | 0.99 (0.86 to 1.14) | 0.876 |
| Cataract | ||||||||
| No | N/A | Reference | Reference | Reference | ||||
| Yes | N/A | N/A | 1.23 (1.17 to 1.31) | <0.001 | 1.05 (0.94 to 1.16) | 0.39 | 1.16 (1.06 to 1.26) | <0.001 |
| Corneal diseases | ||||||||
| No | N/A | Reference | Reference | Reference | ||||
| Yes | N/A | N/A | 1.18 (1.12 to 1.23) | <0.001 | 1.05 (0.96 to 1.15) | 0.322 | 1.08 (1.00 to 1.17) | 0.041 |
| Glaucoma | ||||||||
| No | N/A | Reference | Reference | Reference | ||||
| Yes | N/A | N/A | 1.00 (0.95 to 1.06) | 0.871 | 1.02 (0.92 to 1.12) | 0.773 | 1.04 (0.96 to 1.13) | 0.355 |
| Hyperparathyroidism | ||||||||
| No | Reference | N/A | N/A | N/A | ||||
| Yes | 1.89 (1.42 to 2.52) | <0.001 | N/A | N/A | N/A | N/A | N/A | N/A |
| CCIs | ||||||||
| Every point increase | 1.08 (1.07 to 1.08) | <0.001 | N/A | N/A | N/A | N/A | N/A | N/A |
AMD, age-related macular degeneration; CCIs, Charlson Comorbidity Index score; DM, diabetes mellitus; N/A, the analysis did not perform since it is not necessary for the purpose of the current study.